REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2024 and ...
Q3 2024 Earnings Call Transcript November 6, 2024 Coherus BioSciences, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.1. Operator: Good day, and thank you for standing ...
Developing a vaccination program for infectious bursal disease virus (IBDV) challenges should consider the severity and ...
A central question in adult stem cell biology is elucidating the signaling pathways regulating their dynamics and function in diverse physiological and age-related contexts. Muscle stem cells in ...
Solensia (frunevetmab injection) is a monoclonal antibody drug used for the control of pain associated ... include requesting ...
WSB-TV on MSN1d
Dog parents want arthritis drug pulled from shelves after being linked to hundreds of pet deathsSolensia (frunevetmab injection) is a monoclonal antibody drug used for the control of pain associated ... include requesting ...
Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, USA ...
Serina’s POZ Platform TM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based ...
Net income: The net income attributable to Serina for the three months ended September 30, 2024 was $1.4 million, or $0.16 per share (basic) and $0.13 per share (diluted) compared to net income of ...
Another key priority for our anti-myostatin platform is advancing our novel selective anti-myostatin antibody SRK-439 ... And, of course, more to come, but frankly from FDA's labeling approach, they ...
Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback